Highest-materiality recent filing
P3 Health Partners regains Nasdaq compliance on Listing Rule 5550(b)(2)
Received Nasdaq letter on May 20, 2026 confirming compliance with continued listing standards.
Exchanged ~$252.5M of promissory notes (principal, accrued interest, fees) for non-convertible, non-voting preferred stock.
P3 Health Partners reports Q1 net income $3M, raises FY 2026 adjusted EBITDA guidance to $20-60M
Q1 revenue $386M (+4% YoY); net income $3M vs net loss $44.2M prior year.
P3 converts ~$252.5M debt to preferred stock, raises $10M to regain Nasdaq equity compliance
Exchanged ~$252.5M promissory notes for Series A/B/C preferred stock (13.5%-19.5% dividends) to boost stockholders' equity.
P3 Health Partners reports Q4 net loss $165.7M, provides 2026 EBITDA guidance midpoint $10M
Q4 2025 revenue $384.8M, net loss $165.7M, adjusted EBITDA loss $76.1M.
P3 Health Partners enters Nebraska Medicare Advantage agreement with large nonprofit health insurer
P3 will provide clinical, operational, and data-driven support to primary care providers in client’s Nebraska Medicare Advantage network.
On Nov 21, 2025, Nasdaq notified P3 Health Partners that it lacks the $2.5M minimum stockholders' equity required by Listing Rule 5550(b)(1).
P3 Health Partners forms MSO JV with Commonwealth Primary Care ACO (80/20 split)
P3 subsidiary P3 ACO holds 80% interest; CPC ACO holds 20% in new MSO Delaware LLC.
P3 Health Partners Q3 revenue $345.3M (-5% YoY); adjusted EBITDA loss $45.9M; narrows guidance
At-risk membership ~116k (-10% YoY) due to intentional network/payer rationalization.
P3 Health Partners extends term loan interest-only period to Sep 2026; maturity to Dec 2027
Interest-only period extended to September 30, 2026; maturity extended to December 31, 2027.
P3 Health Partners Q2 revenue down 6% YoY; adj. EBITDA loss $17.1M; FY guidance lowered
Average at-risk membership ~115,000, down 9% YoY due to network/payer rationalization.
P3 Health Partners secures up to $70M unsecured promissory note at 19.5% interest, issues warrants
First tranche $15M drawn; second $15M due by June 22, 2025; third $40M mutually agreed by Dec 31, 2025.
P3 Health Partners Q1 revenue down 4%, medical margin hit by $23M prior-year claims adjustment
Total revenue $373.2M, down 4% YoY; average at-risk membership 115,900 (-8%).
P3 Health Partners effects 1-for-50 reverse stock split effective April 11, 2025
Reverse split applied to Class A and Class V common stock at a 1-for-50 ratio.
P3 Health Partners shareholders approve reverse stock split at 1:10-1:60 ratio
Special Meeting held March 31, 2025; both proposals approved by stockholders.
P3 Health Partners FY2024 net loss widens to $310.4M; revenue up 18% to $1.50B
Full-year net loss $310.4M vs $186.4M prior; adjusted EBITDA loss $167.2M vs $85.5M.
P3 Health Partners secures $30M loan at 19.5% interest, issues warrants for 71.4M shares
$30M unsecured promissory note from VBC Growth SPV 4 (affiliate of principal stockholder), drawn in two $15M tranches.
P3 Health Partners provides preliminary 2025 guidance; proposes $30M note from largest shareholder
Preliminary 2025 revenue guidance of $1.35B-$1.5B; Adjusted EBITDA of $(35)M to $5M.
P3 Health Partners secures $25M financing from affiliate with 71.4M warrants at $0.2137/share
P3 LLC subsidiary entered a $25M unsecured promissory note with VBC 3 at 19.5% interest, maturing June 30, 2028.
P3 Health Q3 revenue $362.1M (+26% YoY) but net loss widens to $102.9M; withdraws FY2024 guidance
Revenue $362.1M, up 26% YoY; capitated revenue $357.7M (+25%).
P3 Health Partners Q2 revenue up 15% to $379.2M; net loss widens to $28.8M
Total revenue $379.2M (+15% YoY); capitated revenue $374.3M (+15% YoY).
P3 Health Partners raises $42.2M in private placement of 67.4M units with warrants
Issued ~67.4M units at ~$0.6270 each; each unit = 1 share Class A + 1 warrant (exercise $0.5020, 7-year term).
P3 Health Partners raises ~$42.2M via private placement of ~67.4M units at $0.627/unit
Gross proceeds of ~$42.2M; each unit priced at ~$0.6270, closing expected May 24, 2024.
Received Nasdaq letter on May 15, 2024 for common stock (PIII) bid price below $1.00 for 31 straight business days.
Dr. Coffman receives $750K base salary, 75% target bonus, and equity awards covering 16.5M shares (12.1M options, 4.4M RSUs).
P3 Health Partners Q1 revenue up 29% to $388.5M; appoints Dr. Aric Coffman as CEO
Total revenue $388.5M (+29% YoY); capitated revenue $384.1M; net loss improved to $49.6M from $52.4M.
P3 Health reports FY23 revenue $1.27B (+21% YoY); affirms 2024 Adj. EBITDA guidance $20M-$40M
Total revenue $1.27B for FY2023 (+21% YoY); net loss $186.4M vs $1.56B prior year.
P3 Health reaffirms 2023 guidance; 2024 revenue $1.45B-$1.55B, positive EBITDA $20M-$40M
FY2023 reaffirmed: revenue $1.2B-$1.25B, medical margin $155M-$175M, Adj. EBITDA loss $30M-$50M.
Q3 total revenue $288.4M, up 16% YoY; net loss $37.3M vs. $65.3M loss prior year.
P3 Health Q2 capitated revenue $325.6M (+22% YoY); Adj EBITDA turns positive at $0.2M
Q2 capitated revenue $325.6M (+22% YoY); medical margin $50.5M (+132%).
P3 Q1 capitated revenue up 11%; net loss improves 14%; medical margin surges 58%
Capitated revenue $298.7M (+11% YoY); net loss $52.4M, improved from $60.8M in Q1 2022.
P3 Health Partners closes $89.5M private placement of common stock and warrants
Raised ~$89.5M gross from sale of 69.2M shares and warrants for 59.9M shares plus pre-funded warrants.
P3 Health Partners Q4 2022 net loss $532.3M on $463.5M goodwill impairment; revenue up 40%
Q4 capitated revenue $254.0M (+40% YoY); net loss $532.3M vs $118.2M loss, primarily due to $463.5M goodwill impairment.
P3 Health Partners raises ~$89.5M in private placement of common stock and warrants
Issued ~69.2M shares, ~59.9M warrants, ~10.8M pre-funded warrants at ~$1.12/unit for institutions, ~$1.19 for employees/consultants.
Reaffirmed FY2022 revenue $1.025B-$1.075B (61%-69% YoY growth) and >100k at-risk MA members.
P3 Health reaffirms 2022 guidance, sees 2023 revenue $1.2B-$1.25B, narrower EBITDA loss
Reaffirmed FY2022 revenue $1.025B-$1.075B (61-69% YoY growth); at-risk MA membership >100k.
On August 29, 2024, the Board of Directors (the “Board”) of P3 Health Partners Inc. (the “Company”) appointed Leif Pedersen as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).
Mr. Pedersen will succeed Atul Kavthekar, who resigned from his position as Chief Financial Officer of the Company effective as of the Effective Date.
Dr. Coffman succeeds Sherif Abdou, M.D., who resigned from his positions as Chief Executive Officer and President of the Company effective as of the Effective Time.
appointed Aric Coffman, M.D. as Chief Executive Officer and President of the Company, effective at 12:00 p.m. Eastern Time on May 8, 2024
the Board appointed Dr. Abdou as Vice Chairperson of the Board. Dr. Abdou will serve as Senior Advisor to the Company’s board of directors and Chief Executive Officer
Erin Darakjian notified P3 Health Partners Inc. (the “Company”) of her resignation as Chief Accounting Officer of the Company, effective as of January 27, 2023
On January 24, 2023, the Board of Directors of the Company designated Atul Kavthekar, the Company’s Chief Financial Officer, as principal accounting officer of the Company, effective as of the Effective Date.
succeeding Ms. Darakjian in such role. Ms. Darakjian remains Chief Accounting Officer, Senior Vice President and principal accounting officer of the Company.
On November 27, 2022, the Board appointed Atul Kavthekar to serve as Chief Financial Officer of the Company, effective as of December 12, 2022.
On October 18, 2022, the Board of Directors (the “Board”) of the Company appointed Erin Darakjian to serve as Interim Chief Financial Officer of the Company, effective as of the Effective Date
On October 14, 2022, Eric Atkins notified the Company of his resignation as Chief Financial Officer of the Company, effective as of November 1, 2022
Max materiality 0.85 · Median 0.70 · Most common event other_material